Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.9 USD | +2.17% | +7.96% | -41.94% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.58B |
---|---|---|---|---|---|
Net income 2024 * | -237M | Net income 2025 * | -271M | EV / Sales 2024 * | - |
Net cash position 2024 * | 478M | Net cash position 2025 * | 693M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.68
x | P/E ratio 2025 * |
-6.32
x | Employees | 120 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.92% |
Latest transcript on Neumora Therapeutics, Inc.
1 day | +2.17% | ||
1 week | +7.96% | ||
1 month | +8.91% | ||
3 months | -43.85% | ||
6 months | -19.18% | ||
Current year | -41.94% |
Managers | Title | Age | Since |
---|---|---|---|
Carol Suh
FOU | Founder | 33 | 19-10-31 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 23-07-17 |
Paul Berns
FOU | Founder | 57 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Berns
FOU | Founder | 57 | 19-10-31 |
May Kin Ho
BRD | Director/Board Member | 71 | 21-03-31 |
Kristina Burow
BRD | Director/Board Member | 50 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.9 | +2.17% | 515,770 |
24-05-30 | 9.69 | +1.89% | 474,476 |
24-05-29 | 9.51 | -.--% | 462,596 |
24-05-28 | 9.51 | +3.71% | 858,545 |
24-05-24 | 9.17 | -1.50% | 285,744 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.94% | 1.58B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- NMRA Stock